اخبار و اعلانات

 آمار

تعداد نشریات286
تعداد نشریات سازمان84
تعداد شماره‌ها2,996
تعداد مقالات33,553
تعداد مشاهده مقاله44,160,765
تعداد دریافت فایل اصل مقاله20,534,090
Heshmati, L, Rezayat, S. M, Madani, R, Emami, T, Jafari, M. R, Golchinfar, F, Kazemi, M, Azimi Dezfouli, S. M. (1400). Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides. سامانه مدیریت نشریات علمی, 76(5), 1183-1190. doi: 10.22092/ari.2021.352498.1566
L Heshmati; S. M Rezayat; R Madani; T Emami; M. R Jafari; F Golchinfar; M Kazemi; S. M Azimi Dezfouli. "Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1183-1190. doi: 10.22092/ari.2021.352498.1566
Heshmati, L, Rezayat, S. M, Madani, R, Emami, T, Jafari, M. R, Golchinfar, F, Kazemi, M, Azimi Dezfouli, S. M. (1400). 'Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides', سامانه مدیریت نشریات علمی, 76(5), pp. 1183-1190. doi: 10.22092/ari.2021.352498.1566
Heshmati, L, Rezayat, S. M, Madani, R, Emami, T, Jafari, M. R, Golchinfar, F, Kazemi, M, Azimi Dezfouli, S. M. Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides. سامانه مدیریت نشریات علمی, 1400; 76(5): 1183-1190. doi: 10.22092/ari.2021.352498.1566

Immunity Evaluation of an Experimental Designed Nanoliposomal Vaccine Containing FMDV Immunodominant Peptides

Archives of Razi Institute
مقاله 6، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1183-1190    اصل مقاله (687.77 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2021.352498.1566
نویسندگان
L Heshmati1؛ S. M Rezayat2، 3، 4؛ R Madani* 5، 6؛ T Emami6؛ M. R Jafari7، 8؛ F Golchinfar6؛ M Kazemi9؛ S. M Azimi Dezfouli10
1Department of Medical Nanotechnology, Faculty of Advanced Sciences and Technology, Tehran Medical Sciences Branch, Islamic Azad University, Tehran, Iran
2Department of Pharmacology and Toxicology, Faculty of Pharmacy, Pharmaceutical Sciences Branch, Islamic Azad University of Tehran, Iran
3Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
4Department of Nanotechnology in Medicine, School of Advanced Technologies in Medicine, Tehran University of Medical Sciences, Tehran, Iran
5Department of Pathobiology, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Iran
6Department of Proteomics and Biochemistry, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization (AREEO), Karaj, Iran
7Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran
8Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
9Department of Biology, Faculty of Sciences, University of Guilan, Rasht, Iran
10Department of Foot and Mouth Vaccine Production, Razi Vaccine and Serum Research Institute, Karaj, Iran Extension Organization (AREEO), Karaj, Iran
چکیده
Foot-and-mouth disease (FMD) is a highly contagious viral disease affecting cloven-hoofed animals. The particular virus causing FMD disease is called FMD virus and is a member of the Aphthovirus genus in the Picornaviridae family. The FMD virus has an 8500 nt long single strain positive RNA genome with one open reading frame (ORF) trapped in an icosahedral capsid protein. This virus genome doesn’t have proofreading property which leads to high mutagenesis. It has seven serotypes, including O, A, ASIA, SAT1, SAT2, and C serotypes, as well as many subtypes. Iran is an endemic region for foot-and-mouth disease. Vaccination of susceptible animals with an inactivated whole-virus vaccine is the only way to control the epidemic in many developing countries. Today, conventionally attenuated and killed virus vaccines are being used worldwide. In Iran, animals have been vaccinated every 105 days with an inactivated FMD vaccine. Although commercially available FMD vaccines are effective, they provide short-term immunity requiring regular boosters. A new FMD vaccine is needed to improve immunization, safety, and long-term immune responses. A synthetic peptide vaccine is one of the safe and important vaccines. Peptide vaccine has low immunogenicity, requiring strong adjuvants. Nanoliposomes can be used as new adjuvants to improve immune response. In the current study, nanoliposomal carriers were selected using Dimyristoylphosphatidylcholine (DMPC), dimyristoyl phosphoglycerol (DMPG), and Cholesterol (Chol) as an adjuvant containing two immunodominant synthetic FMDV peptides. The liposomal formulations were characterized by various physicochemical properties. The size, zeta potential, and encapsulation efficiency were optimized, and the obtained nanoliposome was suitable as a vaccine. The efficacy of vaccines has been evaluated in guinea pigs as animal models. Indirect ELISA was used to detect FMDV-specific IgG. The obtained results indicated that although antibody titer was observed, the amount was lower compared to the groups that received inactivated virus-containing liposomes. In addition, the results showed that liposome was an appropriate adjuvant, compared to other adjuvants, such as Alum and Freund, and can act as a depot and induce an immune response.
کلیدواژه‌ها
Guinean pigs؛ adjuvants؛ ELISA؛ Encapsulation Efficiency
عنوان مقاله [English]
Immunity Evaluation of an experimental designed nanoliposomal vaccine containing FMDV immunodominant peptides
چکیده [English]
Foot-and - mouth disease (FMD) is a highly contagious viral disease affecting cloven-hoofed animals. The particular virus that causes FMD disease is called FMD virus that is a member of the Aphthovirus genus in the Picornaviridae family. FMD virus has a single strain positive RNA genome with a length of 8500 nt with one ORF which are trapped in an icosahedral capsid protein. This virus genome doesn't have proofreading property which tends to highly mutagenesis. It has seven serotypes, such as, O, A, ASIA, SAT1, SAT2 and C and a lot of subtypes. Iran is an endemic region of foot-and - mouth disease. Vaccination of susceptible animals with inactivated whole-virus vaccine is the only way to control the epidemic in many developing countries .Today, conventionally attenuated and killed virus vaccines are being used worldwide. In Iran, animals have been vaccinated every 105 days with an inactivated FMD vaccine. Although commercially available FMD vaccines are effective, they provide short-term immunity requiring regular boosters. A new FMD vaccine is needed to improve immunization, safety and long-term immune responses. A synthetic peptide vaccine is one of the safe and important vaccines. Peptide vaccine has low immunogenicity and applying strong adjuvant is necessary. nanoliposomes as new adjuvants could be used to improve the immune response. In the current study, Nano liposomal carrier as an adjuvant containing two immunodominant synthetic FMDV peptides was selected. The efficacy of the vaccines was evaluated in guinea pigs. Indirect ELISA was used to detect FMDV-specific IgG in the serum of vaccinated guinea pigs.
کلیدواژه‌ها [English]
adjuvants, Guinean pigs, ELISA, IgG, Encapsulation Efficiency
سایر فایل های مرتبط با مقاله
مراجع
  1. Rodriguez LL, Gay CG. Development of vaccines toward the global control and eradication of foot-and-mouth disease. Expert Rev Vaccines. 2011;10(3):377–87.
  2. Motamedi-Sedeh F, Soleimanjahi H, Jalilian AR, Mahravani H, Shafaee K, Sotoodeh M, et al. Development of protective immunity against inactivated Iranian isolate of foot-and-mouth disease virus type O/IRN/2007 using gamma ray-irradiated vaccine on BALB/c mice and Guinea pigs. Intervirology. 2015;58(3):190–6.
  3. Parida S. Vaccination against foot-and-mouth disease virus: Strategies and effectiveness. Expert Rev Vaccines. 2009;8(3):347–65.
  4. Cao Y, Lu Z, Li Y, Sun P, Li D, Li P, et al. Poly(I: C) combined with multi-epitope protein vaccine completely protects against virulent foot-and-mouth disease virus challenge in pigs. Antiviral Res. 2013;97(2):145–53.
  5. Guo HC, Sun SQ, Jin Y, Yang SL, Wei YQ, Sun DH, et al. Foot-and-mouth disease virus-like particles produced by a SUMO fusion protein system in Escherichia coli induce potent protective immune responses in guinea pigs, swine and cattle. Vet Res. 2013;44(1):1–13.
  6. Shao JJ, Wong CK, Lin T, Lee SK, Cong GZ, Sin FWY, et al. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type o in swine. Clin Vaccine Immunol. 2011;18(1):143–9.
  7. Aguilar JC, Rodríguez EG. Vaccine adjuvants revisited. Vaccine. 2007;25(19):3752–62.
  8. Zhang Z, Pan L, Ding Y, Zhou P, Lv J, Chen H, et al. Efficacy of synthetic peptide candidate vaccines against serotype-A foot-and-mouth disease virus in cattle. Appl Microbiol Biotechnol. 2015;99(3):1389–98.
  9. Su D, Van Rooijen N. The role of macrophages in the immunoadjuvant action of liposomes: effects of elimination of splenic macrophages on the immune response against intravenously injected liposome-associated albumin antigen. Immunology. 1989;66(3):466–70.
  10. Gao F, Feng L, Zhang Q, Yan R, Li Y, Li X. Immunogenicity of Two FMDV Nonameric Peptides Encapsulated in Liposomes in Mice and the Protective Efficacy in Guinea Pigs. PloS One. 2013;8(7).
  11. Tabrizi MM, Hosseini SA, Akbarzadeh A. Liposome & Nanotechnology Book. 2017.
  12. Shariat S, Badiee A, Jaafari MR, Mortazavi SA. Optimization of a method to prepare liposomes containing HER2/Neu-derived peptide as a vaccine delivery system for breast cancer. Iran J Pharm Res. 2014;13:15–25.
  1. Smith L. Lowry Determination of Protein X- 100. Anal Biochem. 1975;63:414–7.
  2. Smith MC, Crist RM, Clogston JD, McNeil SE. Zeta potential: a case study of cationic, anionic, and neutral liposomes. Anal Bioanal Chem. 2017;409(24):5779–87.
  3. Anderson M, Omri A. The Effect of Different Lipid Components on the in Vitro Stability and Release Kinetics of Liposome Formulations. Drug Deliv J Deliv Target Ther Agents. 2004;11(1):33–9.
  4. Anzai K, Yoshida M, Kirino Y. Change in intravesicular volume of liposomes by freeze-thaw treatment as studied by the ESR stopped-flow technique. BBA - Biomembr. 1990;1021(1):21–6.
  5. Alving CR. Liposomes as carriers of antigens and adjuvants. J Immunol Methods. 1991;140(1):1–13.
  6. Li J, Wang X, Zhang T, Wang C, Huang Z, Luo X, et al. A review on phospholipids and their main applications in drug delivery systems. Asian J Pharm Sci. 2015;10(2):81–98.
  7. De Serrano LO, Burkhart DJ. Liposomal vaccine formulations as prophylactic agents: Design considerations for modern vaccines. J Nanobiotechnology. 2017;15(1):1–23.
  8. Bagby TR, Cai S, Duan S, Thati S, Aires DJ, Forrest L. Impact of molecular weight on lymphatic drainage of a biopolymer-based imaging agent. Pharmaceutics. 2012;4(2):276–95.
21.          Saravanan P, Sreenivasa BP, Selvan RPT, Basagoudanavar SH, Hosamani M, Reddy ND, et al. Protective immune response to liposome adjuvanted high potency foot-and-mouth disease vaccine in Indian cattle. Vaccine. 2015;33(5):670–7.

آمار
تعداد مشاهده مقاله: 1,990
تعداد دریافت فایل اصل مقاله: 767


counter
سامانه مدیریت نشریات علمی. طراحی و پیاده سازی از سیناوب